-0.18 | -1.26%
| Price and Volume | |
|---|---|
| Recent Price | 14.07 |
| 52 Week High | 16.25 |
| 52 Week Low | 3.93 |
| Avg. Daily Vol. (Mil) | 1.48 |
| Beta (3 year) | 2.08 |
| Share Related Items | |
| Mkt Cap (Mil) | 508.05 |
| Shares Out (Mil) | 36.11 |
| Float (Mil) | 31.09 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.90 |
| Current Ratio | 7.10 |
| LT Debt/ Equity | 0.08 |
| Total Debt / Equity | 0.09 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 5.39 |
| Price/Book | 4.52 |
| Price/Cash Flow | -27.90 |
| Per Share Data | |
| Earnings | -0.62 |
| Sales | 2.61 |
| Book Value | 3.11 |
| Cash Flow | -0.50 |
| Business Summary | |
|---|---|
| Affymax, Inc. is a biopharmaceutical company, which develops novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions. | |
| General Information | |
| 4001 Miranda Avenue
Palo Alto, CA 94304 |
|
| www.affymax.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 130 | |
| CEO: Mr. John A. Orwin | |
| Short Interest | |
| Current Month (Mil) | 4.34 |
| Previous Month (Mil) | 4.40 |
| Short Interest Ratio (Days) | 3.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -12.00 |
| Return on Investments | -16.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -21.40 |
| Profit Margin | -21.60 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.03
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet